Results 171 to 180 of about 34,140,631 (244)

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on retinal endothelial function and oxidative stress during sepsis. [PDF]

Front Pharmacol
Böhm EW, Kouchek Zadeh J, Omran W, Arad T, Pfeiffer N, Wagner FM, Patzak A, Oelze M, Daiber A, Helmstädter J, Steven S, Gericke A.   +11 more
europepmc   +1 more source

Systematic profiling reveals broad G protein coupling and context‐dependent modulation of cyclic AMP by the orphan receptor GPR139

British Journal of Pharmacology, EarlyView.
Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov, Hans Bräuner, Alexander Sebastian Hauser   +2 more
wiley   +1 more source

The Trojan horse of off-label glucagon-like peptide-1 receptor agonist use: Protecting patients through responsible practice. [PDF]

J Int Med Res
Belančić A, Jelaković B.
europepmc   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Depression following the initiation of glucagon-like-peptide-1 receptor agonist therapy: A multinational self-controlled case series study. [PDF]

J Intern Med
Yan VKC, Peng ZY, Wong VKC, Wong ICK, Chan EWY, Ou HT, Wan EYF.   +6 more
europepmc   +1 more source

The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities

British Journal of Pharmacology, EarlyView.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli, Alessia Campagna, Barbara Eramo, Christian Sepe, Annarita Zuena, Silvana Gaetani, Adele Romano   +6 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Gastroenterology Res
Weng J, Huang A, Berake TB, Chen SL, Yan BM, Karagozian R.   +5 more
europepmc   +1 more source

The burden of diabetic foot ulcers in a multi‐ethnic Asian cohort

Diabetic Medicine, EarlyView.
Abstract Aims Diabetic foot ulcers (DFUs) are a major source of morbidity among individuals with diabetes mellitus (DM), imposing a substantial burden on healthcare systems. Our institution established a multidisciplinary service aiming to facilitate early specialist intervention for DFU management.
Zongwen Wee, Yong Mong Bee, Sueziani Binte Zainudin   +2 more
wiley   +1 more source

Photodistributed exfoliative dermatitis associated with semaglutide: Expanding the spectrum of glucagon-like peptide-1 receptor agonist-associated cutaneous reactions. [PDF]

JAAD Case Rep
Kann R, Weitzner Y, Tan C, Chan CX, Amin B, Wieder S.   +5 more
europepmc   +1 more source

Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review

Diabetic Medicine, EarlyView.
Abstract Aims Binge eating disorder frequently co‐occurs with type 2 diabetes, creating a dual burden that may complicate both psychological well‐being and glycaemic management. Evidence on the effectiveness of health interventions in this population is limited.
Pernille Fiil Nybo, Nikolaj Vang Nielsen, Julie Drotner Mouritsen, Michael Einar Røder, Jakob Linnet   +4 more
wiley   +1 more source